Studies on the Synthesis of Specifically Fluorinated 4-Aminopyridine Derivatives by Regioselective Nucleophilic Aromatic Substitution and Catalytic Hydrodefluorination

Gabriel Podolan,^a Phillip Jungk,^{a,b} Dieter Lentz,^a Reinhold Zimmer,^a and Hans-Ulrich Reissig^{a,*}

^a Institut für Chemie und Biochemie, Freie Universität Berlin, Takustr. 3, 14159 Berlin, Germany E-mail: hans.reissig@chemie.fu-berlin.de

^b Current address: Leibniz-Institut für Katalyse e.V. an der Universität Rostock (LIKAT), Albert-Einstein-Str. 29a, 18059 Rostock, Germany

Received: April 21, 2015; Revised: June 17, 2015; Published online: September 15, 2015

Dedicated to the memory of Prof. Manfred Schlosser.

Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/adsc.201500393.

Abstract: The reactions of pentafluoropyridine and 2,4,6-trifluoropyridine with a series of primary and secondary amines were studied. Whereas the nucleophilic aromatic substitution of pentafluoropyridine occurs with high regioselectivity in all cases, providing the expected 4-aminopyridine derivatives in excellent yields, the regioselectivity of 2,4,6-trifluoropyridine is dependent on the steric hindrance of the attacking nucleophile. Small nucleophiles such as morpholine attack the 4-position of the pyridine ring with high preference, but more bulky diamines attack the 2- and 4-positions leading to the formation of three regioisomeric products. (R,R)-1,2-Diaminocyclohexane as moderately bulky diamine reacted with 2,4,6-trifluoropyridine to afford the desired bis(4-aminopyridinyl)cyclohexane derivative in 30% yield. For hydrodefluorination two methods were ex-

Introduction

Aminopyridine derivatives are important compounds in organic synthesis either as final targets, as reagents or as intermediates.^[1] The most famous derivative of this class of heterocycles is 4-(dimethylamino)pyridine (DMAP),^[2] very frequently employed as an efficient Brønsted base in stoichiometric or catalytic amounts.^[3,4] This compound can also function as a powerful Lewis base, for example, in the stabilization of nanoparticles and nanotubes.^[5] We were interested in the synthesis of the new divalent DMAP analogues **A** (Scheme 1) but could not access these new compounds by conventional substitution reactions starting from 4-halopyridines and *trans*-1,2-diamined. A two-step procedure employing hydrazine and subsequently copper(II) sulfate removed just one fluorine substituent, but is not sufficiently high yielding for the reduction of more complex substrates. With the system titanocene difluoride as precatalyst and diphenylsilane as reducing agent we were able to selectively remove fluorine substituents at positions C-2 and C-4 of a variety of 4-aminopyridine derivatives. This protocol allows the synthesis of compounds such as the divalent chiral 4-(dimethylamino)pyridine (DMAP) analogue (R, R)-trans-N, N'dimethyl-N, N'-bis(pyridin-4-yl)cyclohexane-1,2-diamine with fair overall yield.

Keywords: catalysis; fluorine; hydrodefluorination; nucleophilic aromatic substitution; pyridines

aminocyclohexane or by other methods.^[6] However, taking the detour *via* specifically fluorinated aminopyridine derivatives we could finally prepare these target compounds with reasonable efficacy.^[7]

In this full report we want to disclose a detailed description of our approach to these compounds that involves the well known regioselective nucleophilic sub-



Scheme 1. Divalent 4-(dimethylamino)pyridine analogues A.

Gabriel Podolan et al.

stitutions^[8] of 2,4,6-trifluoropyridine or of pentafluoropyridine with the required amines. Subsequently, we describe the experiments to achieve partial or full catalytic hydrodefluorination (HDF)^[9] with known or new catalytic systems to reach our final goal. A series of partially fluorinated aminopyridine derivatives was prepared that may also be of interest as building blocks in medicinal chemistry. It is well established that due to their high electronegativity fluorine atoms strongly alter the physical, chemical and biological properties of compounds^[10] and a high percentage of newly registered drugs or crop protection products contain at least one fluorine atom.

Results and Discussion

Nucleophilic displacement of fluorine in highly fluorinated pyridine derivatives and related heteroaromatic compounds occurs very readily since the heterocyclic system is strongly activated by the presence of the nitrogen atom and the electron-withdrawing fluorine substituents. The regioselectivity of the aromatic nucleophilic substitution processes has been carefully studied. The site-reactivity of pentafluoropyridine (1) follows the sequence 4-fluorine > 2-fluorine > 3-fluorine substituent. The reactions of 1 with various nucleophiles were summarized and discussed in detail.^[8] 2,4,6-Trifluoropyridine (2) was also found to undergo nucleophilic substitution preferentially or exclusively at the 4-position.^[8] Two typical examples^[8i,e] are presented in Scheme 2 revealing the high regioselectivity and the efficacy of this process.



Scheme 2. Regioselective nucleophilic aromatic substitution of pentafluoropyridine (1) and 2,4,6-trifluoropyridine (2) leading to 4-dimethylaminopyridine derivatives 3 and 4.^[8i,e]

Starting with pyridine derivatives 1 and 2 and with morpholine 5 as model nucleophile we obtained the expected monosubstitution products $6^{[8i]}$ and 9, when the reactions were performed at room temperature (Scheme 3). On the other hand, reaction of 1 with a large excess (46 equivalents) of morpholine furnished either a mixture of di- and trisubstituted prod-



Scheme 3. Model reactions of pentafluoropyridine (1) and 2,4,6-trifluoropyridine (2) with morpholine leading to amino-substituted pyridines 6-9 (Morph = morpholinyl).

ucts **7** and **8**, or with the assistance of sodium amide as stronger base the symmetrical trisubstituted compound **8**, exclusively. These transformations confirm the high regioselectivity in favor of the 4-substituted compounds. The subsequent substitution of primarily formed 4-aminopyridine derivative **6** requires an excess of the amine and harsher conditions and finally leads to 2,4,6-trismorpholino-substituted product **8**.

We then investigated the reactivity of vicinal diamines such as the stereoisomers of cyclohexane-1,2diamine. The cis-compound 10 and four equivalents of electrophile 1 provided the expected divalent aminopyridine derivative **11** in excellent vield (Scheme 4). The corresponding (R,R)-stereoisomer 12 gave under similar conditions the enantiopure divalent compound (R,R)-13 in 99% yield. Similar results were obtained with the 1,2-diamino-1,2-diphenylethane derivatives 14 and (S,S)-16 which provided the *meso*-compound 15 and the (S,S)-configured product 17 with high efficacy. Although all transformations required heating to reflux in tetrahydrofuran to achieve these excellent yields, the examples of Scheme 4 confirm the high regioselectivity of nucleophilic substitution reactions of pentafluoropyridine (1).

Next we studied the substitutions employing *N*-methyl-substituted 1,2-diamines. Probably due to the higher steric hindrance the conversions of racemic precursor *rac*-18 and of *meso*-compound 20 into compounds *rac*-19 and 21, respectively, were less efficient



Scheme 4. Synthesis of divalent bis(tetrafluoropyridin-4-yl)-substituted 1,2-diamines 11, (R,R)-13, 15, and (S,S)-17 by nucleophilic substitution of 1 with 1,2-diamines.



Scheme 5. Synthesis of divalent bis(tetrafluoropyridin-4-yl)substituted 1,2-diamines *rac*-19, 21 and 23 by substitution of compound 1.

(Scheme 5). In comparison, the acyclic N,N'-dimethylsubstituted diamine 22 furnished the expected product 23 almost quantitatively; this result is in accord-



Advanced

Catalysis

Synthesis &

Scheme 6. Nucleophilic aromatic substitution of 2,4,6-trifluoropyridine (2) with 1,2-diamine 22 leading to regioisomeric compounds 24, 25 and 26.

ance with the literature reporting a yield of 89% for this compound. $^{[8i]} \ensuremath{\mathsf{B}}$

Whilst the substitutions employing 1 as strong electrophile occurred with very high regioselectivity even with the sterically more hindered secondary amines *rac-18*, 20 and 22, this was no longer the case for the reactions of these nucleophiles with 2,4,6-trifluoropyridine (2). The reaction of four equivalents of this pyridine derivative with 1,2-diamine 22 furnished a mixture of the 2,2-, the 2,4-, and the 4,4-disubstituted products 24–26 in a good overall yield of 85% (Scheme 6). Although the three isomeric products were separable by column chromatography, the synthesis of the desired compound 26 was not very efficient.

The low regioselectivity became fatal when the sterically more hindered *N*-methylated 1,2-diaminocyclohexane derivative *rac*-**18** was employed (Scheme 7). The desired 4,4-disubstituted product *rac*-**31** was only obtained in 1% yield. The two other regioisomers *rac*-



Scheme 7. Nucleophilic aromatic substitutions of 2,4,6-trifluoropyridine (2) with *trans*-1,2-diaminocyclohexane derivatives 18 and 12.

Adv. Synth. Catal. 2015, 357, 3215-3228

© 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim



Scheme 8. Hydrodefluorination of 4-morpholinopyridines 6, 34 and 9 by the two-step method employing hydrazine and copper sulfate.^[11]

27 and *rac*-29 were isolated in 12% and 7% yield, respectively, demonstrating that the substitution is not only unselective, but also quite inefficient. Gratifyingly, the sterically less hindered primary diamine 12 – studied as racemic compound and as enantiopure (R,R)-isomer – behaved much more productively, allowing a synthetically reasonable access to compounds *rac*-32 and (R,R)-32. The process is still not regioselective and the undesired isomers 28 and 30 are formed in relatively high amounts, nevertheless, this route to the desired compound 32 is straightforward considering the simplicity of the method. Again, the three regioisomers were easily separated by column chromatography.

In summary, our results demonstrate an unexpectedly high effect of the steric hindrance of the attacking nucleophile on the regioselectivity of the nucleophilic aromatic substitution with compound **2**. To the best of our knowledge, results showing a similarly strong effect are not known. Apparently, the electronically favored attack at C-4 of 2,4,6-trifluoropyridine (2) becomes unfavorable when bulky secondary amines (such as 18) are employed; in contrast, the reaction at C-2 (or C-6) is less hampered because the adjacent nitrogen atom is unsubstituted. When less bulky primary amines are used this effect could be partially overcome and the 4-substitution occurs in a higher percentage providing the expected products.

With the library of oligofluorinated aminopyridine derivatives in hand, we started to study the hydrode-fluorination of these compounds. The final goal was the preparation of totally defluorinated compounds, either in one step or in a multi-step fashion, but we were also interested whether specifically fluorinated aminopyridines will be accessible by the applied methods. The first results with morpholino-substituted model compounds **6** and **9** as well as with intermediate **34** are collected in Scheme 8. The two-step method of Schlosser et al.^[8e,11] consists in a regioselective nucleophilic substitution of fluoride by hydrazine delivering the 2-hydrazinopyridine derivatives. Subsequent treatment with copper sulfate at 110 °C replaces

the hydrazine moiety by a hydrogen atom. By this method trifluoro compound 34, difluoro compound 36 and monofluoro compound 39 were obtained in moderate to good overall yields. An attempt to introduce two hydrazine substituents at C-2 and C-6 of compound 6 under forcing conditions to give 37 was not successful, thus precluding the direct two-fold defluorination of 6 to 36.

After these encouraging first results we applied this method to divalent aminopyridines 23 and rac-19. In both cases, we observed a substitution with hydrazine at C-2 of both pyridine rings of the substrates, quantitatively leading to the desired intermediates 40 and **42**. Treatment of these compounds with copper sulfate provided the expected products 41 and 43 in moderate yields. Although the two examples demonstrate that the selective removal of one fluorine substituent per pyridine ring is also possible for divalent substrates, the results of Scheme 8 and Scheme 9 indicate that a complete removal by this two-step method would be laborious and probably inefficient.

We also tried to reduce model compound 6 with an excess of samarium diiodide in tetrahydrofuran,^[12] however, no conversion was observed up to temperatures of 70 °C. Next, we examined a catalytic hydrodefluorination method (HDF)^[9] recently developed for fluoroalkenes^[13] employing the pre-catalyst [Cp₂TiF₂] and diphenylsilane as reducing agent.^[14] As test substrates we again used simple 4-morpholinopyridines 6 and 9 and identified 1,4-dioxane and 110°C as optimal conditions. Under these conditions 15 mol% of the pre-catalyst were sufficient to convert both compounds into partially or completely defluorinated products 36 and 44 with excellent efficacy (Scheme 10).

Table 1 summarizes details of our optimization experiments. The use of 1,2-dimethoxyethane as solvent led to a considerable decrease of the reaction rate (entry 4). Full conversion of 6 into 36 was observed only after 96 h (92% yield). The full defluorination of compound 6 to 44 could not be achieved by this method. Higher pre-catalyst loadings and longer reaction times caused decomposition of precursor 6 and/ or the possible intermediates (entry 5).

Table 1. Catalytic HDF of pyridine derivatives 6 and 9 according to Scheme 10.

Entry	Compound	Т [°С]	<i>t</i> [h]	Cp ₂ TiF ₂ [mol%]	Product, Yield
1	6	80	168	50	no reaction
2	6	90	120	24	36 , 81%
3	6	110	24	15	36 , 95%
4 ^[a]	6	110	96	15	36 , 92%
5	6	110	30	100	decomposition
6	9	110	24	15	44 , 98%



Adv. Synth. Catal. 2015, 357, 3215-3228

© 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim



Advanceď

Scheme 9. Two-step hydrodefluorinations of divalent aminopyridine derivatives 23 and rac-19.



Scheme 10. Catalytic hydrodefluorination of model substrates 6 and 9 under optimized conditions employing the [Cp₂TiF₂]/diphenylsilane system.

asc.wiley-vch.de



Scheme 11. Catalytic HDF of divalent octafluoro-substituted pyridines 23, rac-19 and (S,S)-17.

We then turned our attention to the divalent aminopyridine derivatives and applied the optimized conditions to compounds 23, *rac*-19 and (S,S)-17 (Scheme 11). Gratifyingly, the method smoothly worked for the two octafluorinated substrates furnishing the expected tetrafluoro-substituted products 45 and *rac*-46 in good yields. Surprisingly, substrate (S,S)-17 with the 1,2-diphenylamino backbone did not afford product 47, but it underwent complete decomposition. The benzylic positions in the backbone of this substrate possibly lead to side reactions and hence they are not compatible with the reaction conditions of this catalytic HDF method.

To our great pleasure 2,6-tetrafluorinated divalent pyridine derivatives **26** and **32** were very efficiently converted into the fully defluorinated target compounds **48** and **49** in excellent yields (Scheme 12). It should be noted that for the HDF reactions illustrated in Scheme 11 and Scheme 12 30 mol% of pre-catalyst Cp_2TiF_2 are used, in order to guarantee removal of four fluorine atoms from the precursors in reasonable reaction times.

Although the N,N'-dimethyl derivative **31** was directly available by the aromatic nucleophilic substitution (Scheme 7) the low yield of 1% strongly limits the access to this compound. We therefore tried a two-fold N-alkylation of rac-32 in order to gain rac-**31**. Unexpectedly, the first attempt employing a reductive amination with formaldehyde and formic acid furnished the interesting bicyclic compound rac-50 (Scheme 13). Gratifyingly, the direct N-methylation of (R,R)-32 was very efficient, when sodium hydride and methyl iodide were employed. The N-alkylated compounds rac-50 and (R,R)-31 underwent the catalytic HDF with excellent efficacy affording the two new divalent DMAP-analogues 51 and (R,R)-52 in more than 90% yield. An alkylation of (R,R)-32 with 2-iodopropane in order to prepare an analogue of (R,R)-52 with an altered conformation was not successful.



Scheme 12. Complete catalytic HDF of divalent tetrafluoro-substituted divalent pyridines 26 and rac-32.

3220 asc.wiley-vch.de

© 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim



Scheme 13. N-Alkylations of compounds *rac*-32 and (R,R)-32 and subsequent catalytic HDF affording divalent DMAP-analogues *rac*-51 and (R,R)-52.

Conclusions

In this report we have demonstrated that pentafluoropyridine (1) and 2,4,6-trifluoropyridine (2) are suitable starting materials for the short, fairly efficient and versatile syntheses of a library of simple and complex fluorinated 4-aminopyridine derivatives. The removal of all or selected fluorine atoms of the resulting compounds by catalytic hydrodefluorination^[15] or by processes activating the C–F bond leads to new 4-aminopyridine derivatives with unusual substitution patterns. The complete hydrodefluorination of compounds such as (R,R)-**31** led to the desired divalent analogue of 4-(dimethylamino)pyridine (R,R)-**52** that is of interest as a new enantiopure Lewis base and ligand.^[16]

Experimental Section

General Methods

Reactions were generally performed under argon in flamedried flasks. Solvents and reagents were added by syringes. Solvents were dried using standard procedures. Reagents were purchased and were used as received without further purification unless otherwise stated. Reactions were monitored by thin-layer chromatography (TLC). Products were purified by flash chromatography (FLC) on silica gel (32-63 µm). Unless otherwise stated, yields refer to chromatographically homogeneous and spectroscopically pure materials (¹H NMR spectroscopy). NMR spectra were recorded with JEOL (ECX 400, Eclipse 500) instruments. Chemical shifts are reported relative to TMS (¹H: $\delta = 0.00$ ppm) and $CDCl_3$ (¹³C: $\delta = 77.0$ ppm). Integrals are in accordance with assignments; coupling constants are given in Hz. ¹³C NMR spectra are ¹H-decoupled and in most cases ¹⁹F-decoupled. Multiplicity is indicated as follows: s (singlet), d (doublet), t (triplet), m (multiplet), m_c (centered multiplet), dd (doublet of doublet), br s (broad singlet). MS and HR-MS analyses were performed with a Varian Ionspec QFT-7 instrument (ESI-FT ICR-MS). Elemental analyses were carried out with a Vario EL Elemental Analyzer. Melting points were measured with a Reichert apparatus (Thermovar) and are uncorrected.

General Procedure 1 (GP1)

A solution of the amine with pentafluoropyridine (1) or 2,4,6-trifluoropyridine (2) in THF or in CH_2Cl_2 was stirred with Et_3N (4 equiv.) under an Ar atmosphere at room temperature or heated to 70 °C for a certain period of time. After cooling to room temperature the reaction was quenched by water addition. Extraction with Et_2O , solvent evaporation provided the crude product that was purified by flash chromatography (FLC).

Adv. Synth. Catal. 2015, 357, 3215-3228

© 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

4-Substituted tetrafluoropyridine and hydrazine monohydrate were dissolved in ethanol and stirred for the required time under reflux. The mixture was concentrated and the residue was dissolved in CH_2Cl_2 and washed with water. The organic phase was dried and concentrated to give the crude hydrazine derivative. The crude product was suspended in water and the solution of $CuSO_4$ · $5H_2O$ in water was added drop-wise. The resulting mixture was refluxed for 1 h, after cooling down, ammonia solution (25%) was added until pH 9 was reached. Extraction with EtOAc, concentration and purification by FLC furnished the resulting pyridine derivative.

General Procedure 3 (GP3)

The substrate, titanocene difluoride, diphenylsilane and dry 1,4-dioxane were put into a Schlenk flask or a flask equipped with a J. Young PTFE valve and the resulting mixture was subsequently degassed by the freezing vacuum pump method. Subsequently, the mixture was shortly heated with a heat gun until the yellow color changed into darkbrown and the solution was then stirred at 110 °C for the required period (controlled by TLC). The reaction was quenched with MeOH and water was added. Extraction with Et₂O, drying with Na₂SO₄ and concentration furnished the crude product. Purification by FLC furnished the desired product.

2,3,5,6-Tetrafluoro-4-morpholinopyridine (6): According to **GP1**, morpholine (1.31 g, 15.0 mmol) was dissolved in THF (40 mL). A solution of **1** (2.54 g, 15.0 mmol) and Et₃N (5.25 mL, 37.5 mmol, 2.5 equiv.) in THF (4 mL) was added and the resulting mixture was stirred overnight at room temperature. Work-up and FLC (hexanes/EtOAc 5:1) afforded **6** as a colorless solid; yield: 3.49 g (99%, Lit^[8] 90%); mp 51–53 °C, Lit.^[8] 71–73 °C. ¹H NMR (500 MHz, CDCl₃): δ = 3.48 (m_c, 4H, CH₂N), 3.81 (m_c, 4H, CH₂O). The data agree with those of the literature.^[17] ¹³C NMR (125 MHz, CDCl₃): δ = 50.5 (t, CH₂N), 67.0 (t, CH₂O), 135.1, 139.3, 144.9 (3 m_c, C-2, C-3, C-4); ¹⁹F NMR (376 MHz, CDCl₃): δ = –154.3 (m_c, 2F, 3-F), –92.6 (m_c, 2F, 2-F).

3,5,6-Trifluoro-2,4-dimorpholinopyridine (7) and 3,5-Difluoro-2,4,6-trimorpholinopyridine (8): Morpholine (10.0 g, 115 mmol, 46 equiv.), **1** (0.420 g, 2.50 mmol) and Et₃N (2.08 mL, 15.0 mmol, 6 equiv.) were mixed and heated under reflux overnight. Work-up and FLC (hexanes/EtOAc 6:1) afforded **7** [yield: 0.45 g (59%)] and **8** [yield: 0.36 g (39%)] as colorless solids.

7: mp 94–97 °C; ¹H NMR (500 MHz, CDCl₃): δ = 3.31 (m_c, 4H, CH₂N), 3.36 (m_c, 4H, CH₂N), 3.78 (m_c, 8H, CH₂O); ¹³C NMR (125 MHz, CDCl₃): δ = 48.4, 50.8 (2 t, CH₂N), 66.8, 67.3 (2 t, CH₂O), 132.7 (m_c, C-6), 138.6, 139.8, 143.3, 146.3 (4 m_c, C-2, C-3, C-4, C-5); ¹⁹F NMR (376 MHz, CDCl₃): δ = -161.2, -143.1 (2m_c, 2F, 3-F, 5-F), -92.7 (m_c, 1F, 6-F); IR (ATR): \tilde{v} = 2985–2860 (C–H), 1620–1560 (C=C, C=N), 1470, 1190, 1110 (C–F) cm⁻¹; HR-MS (ESI-TOF): m/z = 304.1258, calcd. for C₁₃H₁₆F₃N₃O₂: 304.1267 [M+H]⁺, m/z = 326.1105, calcd. for [M+Na]⁺: 326.1087; anal. calcd. (%) for C₁₃H₁₆F₃N₃O₂ (303.3): C 51.48, H 5.32, N 13.86; found C 51.55, H 5.51, N 14.02.

8: mp 130–132 °C; ¹H NMR (500 MHz, CDCl₃): δ = 3.29 (m_c, 12 H, CH₂N), 3.78 (m_c, 12 H, CH₂O); ¹³C NMR

(125 MHz, CDCl₃): δ = 48.7, 51.1 (2 t, CH₂N), 67.0, 67.5 (2 t, CH₂O), 136.6 (m_c, C-4), 138.6 (m_c, C-3), 143.6 (m_c, C-2); ¹⁹F NMR (376 MHz, CDCl₃): δ = -148.8 (m_c, 2 F, 3-F); IR (ATR): \tilde{v} = 2965–2825 (C–H), 1595, 1565 (C=C, C=N), 1485, 1185, 1110 (C–F) cm⁻¹; HR-MS (ESI-TOF): *m*/*z* = 371.1897,

1185, 1110 (C–F) cm⁻¹; HR-MS (ESI-TOF): m/z = 371.1897, calcd. for $C_{17}H_{24}F_2N_4O_3$: 371.1889 [M+H]⁺, m/z = 393.1716, calcd. for [M+Na]⁺: 393.1709; anal. calcd. (%) for $C_{17}H_{24}F_2N_4O_3$ (370.4): C 55.13, H 6.53, N 15.13; found C 55.22, H 6.44, N 15.40.

Sodium amide (0.490 g, 12.5 mmol, 5 equiv.) was suspended in morpholine (10 mL, 115 mmol, 46 equiv.), pyridine derivative **1** (0.420 g, 2.50 mmol) was added and the resulting mixture was heated under reflux for 24 h. The reaction was quenched with saturated aqueous NH_4Cl solution, then extraction (EtOAc) and FLC (hexanes/EtOAc, 4:1) gave **8** as a colorless solid; yield: 717 mg (78%).

2,6-Difluoro-4-morpholinopyridine (9): According to **GP1**, morpholine (0.360 g, 4.00 mmol) and Et_3N (1.40 mL, 10.0 mmol, 2.5 equiv.) were dissolved in CH₂Cl₂ (9 mL). A solution of 2 (0.540 g, 4.00 mmol) in CH₂Cl₂ (2 mL) was added and the mixture was stirred overnight at room temperature. Work-up and FLC (hexanes/EtOAc 3:1) gave 9 as a colorless solid; yield: 0.711 g (89%); mp 201-202°C; ¹H NMR (500 MHz, acetone- d_6): $\delta = 3.43$ (t, J = 5.1 Hz, 4 H, CH₂N), 3.77 (t, J=5.1 Hz, 4H, CH₂O), 6.37 (m_c, 2H, 3-H, 5-H); ¹³C NMR (125 MHz, acetone- d_6): $\delta = 47.3$ (t, CH₂N), 66.7 (t, CH₂O), 89.5 (m_c, C-3), 163.2 (t, $J_{C,F}$ =12.0 Hz, C-4), 164.5 (dd, J_{CF} =235, 21.6 Hz, C-2); ¹⁹F NMR (376 MHz, acetone- d_6): $\delta = -73.0$ (s, 2 F, 2-F); IR (ATR): $\tilde{v} = 3125$ (=C-H), 2970-2865 (C-H), 1660-1530 (C=C, C=N), 1450, 1235, 1210, 1120 (C-F) cm⁻¹; HR-MS (ESI-TOF): m/z =201.0832, calcd. for C₉H₁₀F₂N₂O: 201.0834 [M+H]⁺, m/z =223.0652, calcd. for [M+Na]⁺: 223.0653; anal. calcd. (%) for $C_9 H_{10} F_2 N_2 O$ (200.2): C 54.00, H 5.04, N 13.99; found C 54.19, H 5.19, N 14.08.

cis-N,N'-Bis(2,3,5,6-tetrafluoropyridin-4-yl)cyclohexane-**1,2-diamine (11):** According to **GP1**, *cis*-cyclohexane-1,2-diamine (10) (0.100 g, 0.870 mmol) and Et_3N (0.490 mL, 3.48 mmol, 4 equiv.) were dissolved in THF (5 mL). A solution of 1 (0.565 g, 3.34 mmol, 4 equiv.) in THF (1 mL) was added and the mixture was stirred for 24 h under reflux. Work-up and FLC (hexanes/EtOAc 6:1) afforded 12 as a colorless solid; yield: 0.348 g (97%); mp 92-94°C. 1H NMR $(500 \text{ MHz}, \text{ CDCl}_3): \delta = 1.56 - 1.74 \text{ (m, 6H, CH}_2), 1.85 - 1.91$ (m, 2H, CH₂), 4.26 (m_c, 2H, CH), 4.69 (m_c, 2H, NH); ¹³C NMR (125 MHz, CDCl₃): $\delta = 21.3$ (t, CH₂), 29.2 (t, CH₂), 54.0 (dt, J_{CF}=4.4 Hz, CH), 131.7 (m_c, C-2/C-3), 136.7 (m_c, C-4), 144.3 (m_c, C-2/C-3); ¹⁹F NMR (376 MHz, CDCl₃): $\delta = -162.3 \text{ (m}_{c}, 4\text{ F}, 3\text{-F}), -93.1 \text{ (m}_{c}, 4\text{ F}, 2\text{-F}); \text{HR-MS (ESI-}$ TOF): m/z = 413.1033, calcd. for C₁₆H₁₂F₈N₄: 413.1012 [M+ H]⁺, m/z = 435.0839, calcd. for [M+Na]⁺: 435.0832.

(*R*,*R*)-*N*,*N*'-Bis(2,3,5,6-tetrafluoropyridin-4-yl)cyclohexane-1,2-diamine (13): According to GP1, (*R*,*R*)-cyclohexane-1,2-diamine (12) (0.100 g, 0.870 mmol) and Et₃N (0.490 mL, 3.48 mmol, 4 equiv.) were dissolved in THF (5 mL). A solution of 1 (0.565 g, 3.34 mmol, 4 equiv.) in THF (1 mL) was added and the mixture was stirred for 24 h under reflux. Work-up and FLC (hexanes/EtOAc 5:1) afforded 13 as a colorless solid; yield: 0.360 g (99%); mp 125– 127 °C; $[\alpha]_{D}^{20}$: +103.4 (*c*=1.5, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ =1.42 (m_c, 4H, CH₂), 1.89 (m_c, 2H, CH₂), 2.24 (m_c, 2H, CH₂), 3.77 (m_c, 2H, CH), 4.49 (m_c, 2H, NH); ¹³C NMR (125 MHz, CDCl₃): δ =24.6 (t, CH₂), 34.2 (t, CH₂), 59.4 (m_c, CH), 131.0 (m_c, C-2/C-3), 137.0 (m_c, C-4), 144.1 (m_c, C-2/C-3); ¹⁹F NMR (376 MHz, CDCl₃): δ = -162.4 (m_c, 4F, 3-F), -93.2 (m_c, 4F, 2-F); HR-MS (ESI-TOF): *m*/*z*=413.1002, calcd. for C₁₆H₁₂F₈N₄: 413.1012 [M+H]⁺, *m*/*z*=435.0836, calcd. for [M+Na]⁺: 435.0832.

meso-N,N'-Bis(2,3,5,6-tetrafluoropyridin-4-yl)-1,2-diphenylethane-1,2-diamine (15): According to GP1, meso-1,2-diphenylethane-1,2-diamine (14) (0.150 g, 0.710 mmol) and Et₃N (0.400 mL, 2.83 mmol, 4 equiv.) were dissolved in THF (5 mL). A solution of 1 (0.458 g, 2.72 mmol, 4 equiv.) in THF (1 mL) was added and the mixture was stirred for 24 h under reflux. Work-up and FLC (hexanes/EtOAc 6:1) afforded **15** as a slightly vellow solid; yield: 0.361 g (quant.); mp 176–178°C. ¹H NMR (500 MHz, acetone- d_6): $\delta = 5.78$ (m_c, 2H, CH), 6.74 (m_c, 2H, NH), 7.24 (m_c, 2H, Ph), 7.34 (m_c, 4H, Ph), 7.72 (m_c, 4H, Ph); ¹³C NMR (125 MHz, acetone- d_6): $\delta = 62.4$ (dt, $J_{CF} = 4.9$ Hz, CH), 127.8 (d, Ph), 128.2 (d, Ph), 128.6 (d, Ph), 131.3 (m_c, C-2/C-3), 136.0 (m_c, C-4), 140.2 (s, Ph), 144.0 (m_c, C-2/C-3); ¹⁹F NMR (376 MHz, CDCl₃): $\delta = -161.6 (m_c, 4F, 3-F), -96.8 (m_c, 4F, 2-F);$ HR-MS (ESI-TOF): m/z = 511.1170, calcd. for $C_{24}H_{14}F_8N_4$ [M+ H]⁺: 511.1169, m/z = 533.0991, calcd. for [M+Na]⁺: 533.0988.

(S,S)-N,N'-Bis(2,3,5,6-tetrafluoropyridin-4-yl)-1,2-diphenylethane-1,2-diamine (17): According to GP1, (S,S)-1,2-diphenylethane-1,2-diamine (16) (0.150 g, 0.710 mmol) and Et₃N (0.400 mL, 2.83 mmol, 4 equiv.) were dissolved in THF (5 mL). A solution of **1** (0.458 g, 2.72 mmol, 4 equiv.) in THF (1 mL) was added and the mixture was stirred for 24 h under reflux. Work-up and FLC (hexanes/EtOAc 5:1) afforded 17 as a colorless solid; yield: 0.355 g, (98%); 159-161°C; $[\alpha]_{D}^{20}$: -62.1 (c=1.3, CHCl₃). ¹H NMR (500 MHz, CDCl₃): $\delta = 5.14$ (br s, 2H, NH), 5.28 (m_c, 2H, CH), 6.96 (m_c, 4H, Ph), 7.21–7.33 (m, 6H, Ph); ¹³C NMR (125 MHz, CDCl₃): $\delta = 63.1$ (dt, $J_{CF} = 4.1$ Hz, CH), 127.3 (d, Ph), 129.1 (d, Ph), 129.2 (d, Ph), 131.8 (m_c, C-2/C-3), 136.4 (m_c, C-4), 136.5 (s, Ph), 144.2 (m_c, C-2/C-3); ¹⁹F NMR (376 MHz, CDCl₃): $\delta = -160.8$ (m_c, 4F, 3-F), -92.5 (m_c, 4F, 2-F); HR-MS (ESI-TOF): m/z = 511.1171, calcd. for $C_{24}H_{14}F_8N_4$: 511.1169 $[M+H]^+$, m/z = 533.1001, calcd. for $[M+Na]^+$: 533.0988.

rac-trans-N,N'-Dimethyl-N,N'-bis(2,3,5,6-tetrafluoropyridin-4-yl)cyclohexane-1,2-diamine (19): According to GP1, rac-trans-N,N'-dimethylcyclohexane-1,2-diamine (18)(0.280 g, 1.97 mmol) and Et_3N (1.11 mL, 1.11 mL)7.90 mmol, 4 equiv.) were dissolved in THF (20 mL). A solution of 1 (1.33 g, 7.87 mmol, 4 equiv.) in THF (5 mL) was added and the resulting mixture was stirred for 2 d under reflux. Work-up and FLC (hexanes/EtOAc 15:1) afforded 19 as a colorless solid; yield: 0.400 g (46%); mp 216-217°C. ¹H NMR (500 MHz, CDCl₃): $\delta = 1.36$ (m_c, 2H, CH₂), 1.71– 1.73 (m, 2H, CH₂), 1.82–1.94 (m, 2H, CH₂), 2.11–2.13 (m, 2H, CH₂), 2.76 (t, J_{HF}=3.1 Hz, 6H, CH₃), 3.58–3.69 (m, 2H, CH); ¹³C NMR (125 MHz, CDCl₃): $\delta = 25.1$ (t, CH₂), 30.2 (t, CH₂), 33.5 (q, CH₃), 61.9 (d, CH), 134.6, 140.7, 145.2 (3 m_c, C-2, C-3, C-4); ¹⁹F NMR (376 MHz, CDCl₃): $\delta = -154.2$ (m_c, 4F, 3-F), -92.7 (m_c, 4F, 2-F); IR (ATR): $\tilde{v} = 2955 - 2835$ (C-H), 1635, 1525 (C=C, C=N), 1465, 1220, 1160, 1110 (C-F) cm⁻¹; HR-MS (ESI-TOF): m/z = 441.1315, calcd. for $C_{18}H_{16}F_8N_4$: 441.1320 [M+H]⁺, m/z = 463.1136, calcd. for $[M+Na]^{+}\!\!:463.1139;$ anal. calcd. (%) for $C_{18}H_{16}F_8N_4$ (440.3): C 49.10, H 3.66, N 12.72; found: C 49.12, H 3.45, N 12.87.

Advanced 🔊

Catalysis

Synthesis &

cis-N,N'-Dimethyl-N,N'-bis(2,3,5,6-tetrafluoropyridin-4yl)cyclohexane-1,2-diamine (21): According to GP1, cis-*N*,*N*'-dimethylcyclohexane-1,2-diamine (20)(0.100 g, 0.70 mmol) and Et₃N (0.40 mL, 2.81 mmol, 4 equiv.) were dissolved in THF (5 mL). A solution of 1 (0.26 g, 1.54 mmol, 2.2 equiv.) in THF (2 mL) was added and the resulting mixture was stirred for 2 d under reflux. Work-up and FLC (hexanes/EtOAc 15:1) afforded 21 as a brownish foam; yield: 0.127 g (41%). ¹H NMR (400 MHz, CDCl₃): $\delta = 1.51$ (m_c, 2H, CH₂), 1.77–1.81 (m, 4H, CH₂), 2.02–2.10 (m, 2H, CH₂), 2.76 (m_c, 6H, CH₃), 3.72–3.83 (m, 2H, CH); ¹³C NMR (125 MHz, CDCl₃): $\delta = 23.9$ (t, CH₂), 28.4 (t, CH₂), 38.9 (q, CH₃), 61.2 (d, CH), 134.2, 138.2, 145.4 (3 m_c, C-2, C-3, C-4); ¹⁹F NMR (376 MHz, CDCl₃): $\delta = -155.1$ (m_c, 4F, 3-F), -95.8 $(m_c, 4F, 2-F)$; HR-MS (ESI-TOF): m/z = 441.1324, calcd. for $C_{18}H_{16}F_8N_4$: 441.1320 [M+H]⁺.

N,N'-Dimethyl-N,N'-bis(2,3,5,6-tetrafluoropyridin-4-yl)ethane-1,2-diamine (23): According to GP1, N,N'-dimethylethylene-1,2-diamine (22) (0.29 g, 3.30 mmol) and Et₃N (1.87 mL, 13.3 mmol, 4 equiv.) were dissolved in THF (20 mL). A solution of pentafluoropyridine (1) (1.13 g, 6.68 mmol, 2 equiv.) in THF (15 mL) was added and the resulting mixture was stirred overnight at room temperature. Work-up and following FLC (hexanes/ethyl acetate 6:1) afforded product 23 as a colorless solid; yield: 1.28 g (99%, lit.^[8i] 90%); mp 140–141 °C (lit.^[8i] 139–140 °C). ¹H NMR (CDCl₃, 500 MHz): $\delta = 3.15$ (t, J = 3.3 Hz, 6 H, CH₃), 3.64 (s, 4 H, CH₂); ¹³C NMR (CDCl₃, 125 MHz): $\delta = 40.8$ (q, CH₃), 52.7 (t, CH₂), 134.5, 139.8, 145.1 (3 s, C-2, C-3, C-4); ¹⁹F NMR (CDCl₃, 471 MHz): $\delta = -155.3$ (m_c, 4F, 3-F), -92.7 (m_c, 4F, 2-F); IR (ATR): \tilde{v} =2990–2835 (C–H), 1630, 1530 (C=C, C=N), 1460, 1260, 1220, 1130, 1115 (C-F) cm⁻¹; HR-MS (ESI-TOF): m/z = 387.0826, calcd. for $C_{14}H_{10}F_8N_4$: 387.0850 $[M+H]^+$, m/z = 409.0649, calcd. for $[M+Na]^+$: 409.0670; anal. calcd. (%) for $C_{14}H_{10}F_8N_4$ (386.2): C 43.53, H 2.61, N 14.51; found: C 43.49, H 2.51, N 14.39.

N,N'-Dimethyl-N,N'-bis(4,6-difluoropyridin-2-yl)ethane-1,2-diamine (24), N,N'-dimethyl-N-(2,6-difluoropyridin-4yl)-N'-(4,6-difluoropyridin-2-yl)ethane-1,2-diamine (25) and N,N'-dimethyl-N,N'-bis(2,6-difluoropyridin-4-yl)ethane-1,2diamine (26): According to GP1, N,N'-dimethylethylene-1,2diamine (22) (0.220 g, 2.50 mmol) and Et₃N (1.40 mL, 10.0 mmol, 4 equiv.) were dissolved in THF (20 mL). A solution of 2 (0.670 g, 5.00 mmol, 2 equiv.) in THF (5 mL) was added and the mixture was stirred overnight under reflux. Work-up and FLC (hexanes/EtOAc 12:1, 8:1, 3:1) afforded 24 (yield: 0.143 g, 18%), 25 (yield: 0.235 g, 30%) and 26 (0.290 g, 37%) as a colorless solids.

24: mp 177–178 °C; ¹H NMR (500 MHz, acetone- d_6): $\delta = 2.99$ (s, 6H, CH₃), 3.71 (s, 4H, CH₂), 5.85 (m_c, 2H, 3-H/5-H), 5.96 (m_c, 2H, 3-H/5-H); ¹³C NMR (125 MHz, acetone- d_6): $\delta = 37.2$ (q, CH₃), 47.6 (t, CH₂), 84.6 (ddd, J_{CF} =42.3, 24.8 Hz, C-3/C-5), 89.9 (ddd, J_{CF} =23.8, 5.7 Hz, C-3/C-5), 158.4 (dd, J_{CF} =20.1, 14.0 Hz, C-2), 163.7 (dd, J_{CF} =233, 18.3 Hz, C-6), 172.9 (dd, J_{CF} =254, 14.8 Hz, C-4); ¹⁹F NMR (376 MHz, acetone- d_6): $\delta = -98.7$ (m_c, 2F, 4-F), -65.5 (m_c, 2F, 6-F); IR (ATR): $\tilde{\nu}$ =3120, 3100 (=C-H), 2925–2810 (C-H), 1710–1510 (C=C, C=N), 1455, 1260, 1180, 1110 (C-F) cm⁻¹; HR-MS (ESI-TOF): m/z=315.1240, calcd. for C₁₄H₁₄F₄N₄: 315.1227 [M+H]⁺, m/z=337.1060, calcd. for

$$\label{eq:main_state} \begin{split} & [M+Na]^+\!\!\!: 337.1047; \mbox{ anal. calcd. (\%) for $C_{14}H_{14}F_4N_4$ (314.3): C 53.50, H 4.49, N 17.83; found: C 53.31, H 4.57, N 17.90. \end{split}$$

25; mp 194–195 °C; ¹H NMR (500 MHz, acetone- d_6): $\delta =$ 3.08 (s, 3H, CH₃), 3.10 (s, 3H, CH₃), 3.69 (m_c, 2H, CH₂), 3.81 (m_c, 2H, CH₂), 6.06 (m_c, 1H, 3'-H/5'-H), 6.19 (m_c, 1H, 3'-H/5'-H), 6.25 (br s, 2H, 3-H/5-H); ¹³C NMR (125 MHz, acetone- d_6): $\delta = 37.5$, 38.8 (2 q, CH₃), 47.6, 49.9 (2 t, CH₂), 84.6 (ddd, J_{CF}=42.7, 25.1 Hz, C-3'/C-5'), 88.2 (m_c, C-3/C-5), 89.9 (ddd, J_{CF} =23.9, 5.6 Hz, C-3'/C-5'), 159.7 (dd, J_{CF} =20.3, 14.1 Hz, C-2'), 162.2 (dd, J_{CF} =12.0 Hz, C-4), 164.1 (dd, $J_{\rm CF}$ =232, 18.1 Hz, C-6'), 164.7 (dd, $J_{\rm CF}$ =234, 22.2 Hz, C-2/ C-6), 173.4 (dd, $J_{CF}=252$, 14.6 Hz, C-4'); ¹⁹F NMR (376 MHz, acetone- d_6): $\delta = -100.3$ (m_c, 1F, 4'-F), -73.6 (s, 2F, 2-F), -66.6 (d, J_{EF} =22.9 Hz, 1F, 6'-F); IR (ATR): \tilde{v} = 3100 (=C-H), 2925-2815 (C-H), 1620-1510 (C=C, C=N), 1450, 1265, 1170, 1150, 1120 (C-F) cm⁻¹; HR-MS (ESI-TOF): m/z = 315.1239, calcd. for $C_{14}H_{14}F_4N_4$: 315.1227 [M+ H]⁺, m/z = 337.1061, calcd. for [M+Na]⁺: 337.1047; anal. calcd. (%) for C₁₄H₁₄F₄N₄ (314.3): C 53.50, H 4.49, N 17.83; found: C 53.43, H 4.49, N 17.78.

26: mp 188–189 °C; ¹H NMR (500 MHz, acetone- d_6): δ = 3.08 (s, 6H, CH₃), 3.82 (s, 4H, CH₂), 6.14 (m_c, 4H, 3-H/5-H); ¹³C NMR (125 MHz, acetone- d_6): δ = 39.2 (q, CH₃), 49.8 (t, CH₂), 88.3 (dd, J_{CF} =45.5 Hz, C-3/C-5), 161.5 (t, J_{CF} = 12.2 Hz, C-4), 164.4 (dd, J_{CF} =234, 21.9 Hz, C-2); ¹⁹F NMR (376 MHz, acetone- d_6): δ = -73.2 (s, 4F, 2-F); IR (ATR): $\tilde{\nu}$ =3100 (=C-H), 2925–2855 (C-H), 1735–1520 (C=C, C=N), 1440, 1240, 1170 (C-F) cm⁻¹; HR-MS (ESI-TOF): m/z=315.1201, calcd. for C₁₄H₁₄F₄N₄: 315.1227 [M+H]⁺, m/z=337.1023, calcd. for [M+Na]⁺: 337.1047; calcd. (%) for C₁₄H₁₄F₄N₄ (314.3): C 53.50, H 4.49, N 17.83; found: C 53.31, H 4.49, N 17.60.

rac-trans-N,N'-Dimethyl-*N,N'*-bis(4,6-difluoropyridin-2yl)cyclohexane-1,2-diamine (27), *rac-trans-N,N'*-dimethyl-*N*-(2,6-difluoropyridin-4-yl)-*N'*-(4,6-difluoropyridin-2-yl)cyclohexane-1,2-diamine (29) and *rac-trans-N,N'*-dimethyl-*N,N'*-bis(2,6-difluoropyridin-4-yl)cyclohexane-1,2-diamine (31): According to GP1, *rac-trans*-18 (1.12 g, 7.85 mmol) and Et₃N (4.41 mL, 31.4 mmol, 4 equiv.) were dissolved in THF (100 mL). A solution of 2 (4.18 g, 31.4 mmol, 4 equiv.) in THF (5 mL) was added and the mixture was refluxed for 72 h. Work-up and FLC (hexanes/EtOAc 15:1, 10:1, 5:1) afforded 27 (yield: 0.358 g, 12%), 29 (yield: 0.202 g, 7%) and 31 (0.026 g, 1%) as colorless solids.

27: mp 74–76 °C; ¹H NMR (500 MHz, acetone- d_6): $\delta =$ 1.47 (m_c, 2H, CH₂), 1.77-1.83 (m, 6H, CH₂), 2.75 (s, 6H, CH₃), 4.81 (br s, 2H, CH), 5.97 (m_c, 2H, 3-H/5-H), 6.09 (m_c, 2H, 3-H/5-H); ¹³C NMR (125 MHz, acetone- d_6): $\delta = 25.3$ (t, CH₂), 30.0 (t, CH₂), 31.0 (q, CH₃), 56.0 (d, CH), 84.2 (ddd, J_{CF} =43.9, 25.2 Hz, C-3/C-5), 89.0 (ddd, J_{CF} =23.9, 5.5 Hz, C-3/C-5), 159.8 (dd, $J_{C,F}$ =20.7, 14.4 Hz, C-2), 164.3 (dd, *J*_{C,F}=231, 18.0 Hz, C-6), 173.5 (dd, *J*_{C,F}=253, 14.1 Hz, C-4); ¹⁹F NMR (376 MHz, acetone- d_6): $\delta = -100.5$ (m_c, 2F, 4-F), -66.4 (d, $J_{F,F}=23.2$ Hz, 2F, 6-F); IR (ATR): $\tilde{v}=3105$ (=C-H), 2930, 2860, 2815 (C-H), 1625, 1565 (C=C, C=N), 1495, 1190, 1160, 1115 (C-F) cm⁻¹; HR-MS (ESI-TOF): m/z = 369.1699, calcd. for $C_{18}H_{20}F_4N_4$: 369.1697 [M+H]⁺, m/z = 391.1516, calcd. for [M+Na]⁺: 391.1516; anal. calcd. (%) for C₁₈H₂₀F₄N₄ (368.4): C 58.69, H 5.47, N 15.21; found: C 58.81, H 5.56, N 15.12.

29: mp 105–107 °C; ¹H NMR (500 MHz, acetone- d_6): $\delta =$ 1.48–1.64 (m, 2 H, CH₂), 1.74–1.90 (m, 6 H, CH₂), 2.77, 2.79

(2 s, 3 H each, CH₃), 4.22, 4.87 (2 m_c, 1 H each, CH), 6.01 (m_c, 1H, 3'-H/5'-H), 6.15 (m_c, 1H, 3'-H/5'-H), 6.26 (br s, 2H, 3-H/5-H); ¹³C NMR (125 MHz, acetone- d_6): $\delta = 25.4$, 25.7, 29.7, 29.9 (4 t, CH₂), 32.3 (q, CH₃), 58.9 (d, CH), 84.5 (ddd, $J_{CF} = 43.7, 25.2 \text{ Hz}, \text{ C-3'/C-5'}, 88.2 \text{ (m}_{c}, \text{ C-3/C-5)}, 90.0 \text{ (ddd,}$ J_{CF} =24.0, 5.3 Hz, C-3'/C-5'), 159.6 (dd, J_{CF} =20.7, 14.3 Hz, C-2'), 162.0 (t, $J_{CF}=12.2$ Hz, C-4), 164.3 (dd, $J_{CF}=231$, 17.9 Hz, C-6'), 164.5 (dd, J_{CF}=233, 21.9 Hz, C-2/C-6), 173.5 (dd, J_{CF} =253, 14.1 Hz, C-4'); ¹⁹F NMR (376 MHz, acetone d_6): $\delta = -100.3$ (m_c, 1 F, 4'-F), -73.7 (m_c, 2F, 2-F), -66.4 (d, $J_{\rm EF} = 22.9$ Hz, 1 F, 6'-F); IR (ATR): $\tilde{v} = 2935$, 2860 (C-H), 1620, 1570, 1545 (C=C, C=N), 1495, 1240 1190, 1120 (C-F) cm⁻¹; HR-MS (ESI-TOF): m/z = 369.1699, calcd. for $C_{18}H_{20}F_4N_4$: 369.1697 [M+H]⁺, m/z = 391.1524, calcd. for $[M + Na]^+$: 391.1516; anal. calcd. (%) for $C_{18}H_{20}F_4N_4$ (368.4): C 58.69, H 5.47, N 15.21; found: C 58.74, H 5.64, N 15.09.

31: mp 196–197 °C; ¹H NMR (500 MHz, acetone- d_6): $\delta = 1.59$ –1.69 (m, 2H, CH₂), 1.82–1.87 (m, 6H, CH₂), 2.80 (s, 6H, CH₃), 4.27 (m_c, 2H, CH), 6.31 (s, 4H, 3-H/5-H); ¹³C NMR (125 MHz, acetone- d_6): $\delta = 25.2$ (t, CH₂), 29.5 (t, CH₂), 32.1 (q, CH₃), 59.1 (d, CH), 88.3 (m_c, C-3/C-5), 161.9 (t, $J_{CF}=12.2$ Hz, C-4), 164.5 (dd, $J_{CF}=233$, 21.9 Hz, C-2); ¹⁹F NMR (376 MHz, acetone- d_6): $\delta = -73.4$ (s, 4F, 2-F); IR (ATR): $\tilde{\nu} = 3085$ (=C–H), 2930, 2860 (C–H), 1635, 1545, 1510 (C=C, C=N), 1445, 1220, 1190, 1130 (C–F) cm⁻¹; HR-MS (ESI-TOF): m/z = 369.1699, calcd. for C₁₈H₂₀F₄N₄: 369.1697 [M+H]⁺, m/z = 391.1521, calcd. for [M+Na]⁺: 391.1516.

rac-trans- or (R,R)-*N*,*N'*-Bis(4,6-difluoropyridin-2-yl)cyclohexane-1,2-diamine (28), *rac-trans-* or (R,R)-*N*-(2,6-difluoropyridin-4-yl)-*N'*-(4,6-difluoropyridin-2-yl)cyclohexane-1,2-diamine (30) and *rac-trans-* or (R,R)-*N*,*N'*-bis(2,6-difluoro-pyridin-4-yl)cyclohexane-1,2-diamine (32): According to GP1, *rac-trans-*12 (0.500 g, 4.38 mmol) and Et₃N (2.45 mL, 17.5 mmol, 4 equiv.) were dissolved in THF (10 mL). A solution of 2 (2.33 g, 17.5 mmol, 4 equiv.) in THF (5 mL) was added and the resulting mixture was stirred for 36 h under reflux. Work-up and FLC (hexanes/ EtOAc 6:1, 4:1, 1:1) afforded 28 (yield: 0.200 g, 13%), 30 (yield: 0.616 g, 41%) and 32 (yield: 0.370 g, 25%) as colorless solids.

The experiment was also performed with (R,R)-12 to give the enantiopure products in almost identical yields: 13% for 28, 45% for 30 and 30% for 32.

28: mp 141–143 °C [147–149 °C for the *R*,*R*-isomer, $[\alpha]_D^{20}$: +68.5 (*c*=1.04, CHCl₃)]; ¹H NMR (500 MHz, CDCl₃): δ = 1.24–1.35 (m, 2H, CH₂), 1.36–1.43 (m, 2H, CH₂), 1.77 (m_c, 2H, CH₂), 2.14 (m_c, 2H, CH₂), 3.55 (m_c, 2H, CH₂), 5.68 (m_c, 2H, 3-H/5-H), 5.81 (m_c, 2H, 3-H/5-H); ¹³C NMR (125 MHz, CDCl₃): δ =24.6 (t, CH₂), 32.6 (t, CH₂), 55.7 (d, CH), 85.0 (ddd, $J_{C,F}$ =41.7, 24.9 Hz, C-3/C-5), 90.1 (m_c, C-3/C-5), 158.6 (ddd, $J_{C,F}$ =20.7, 14.2 Hz, C-2), 164.1 (ddd, $J_{C,F}$ =235, 17.2 Hz, C-6), 172.2 (ddd, $J_{C,F}$ =256, 14.0 Hz, C-4); ¹⁹F NMR (376 MHz, CDCl₃): δ =-98.7 (m_c, 2F, 4-F), -66.8 (m_c, 2F, 6-F); HR-MS (ESI-TOF): *m*/*z*=341.1384, calcd. for C₁₆H₁₆F₄N₄: 341.1389 [M+H]⁺.

30: mp 137–139 °C [131–133 °C for the *R*,*R*-isomer, $[\alpha]_D^{20}$: +135.4 (*c*=1.04, CHCl₃)]; ¹H NMR (500 MHz, CDCl₃): δ = 1.23–1.47 (m, 4H, CH₂), 1.77–1.86 (m, 2H, CH₂), 2.08 (m_c, 1H, CH₂), 2.19 (m_c, 1H, CH₂), 3.12 (dt, *J*=10.0, 8.6 Hz, 1H, CH), 3.89 (dt, *J*=10.0, 8.9 Hz, 1H, CH), 4.75 (m_c, 1H, NH), 5.74 (s, 2H, 3-H/5-H), 5.91 (m_c, 2H, 3'-H/5'-H), 6.02 (m_c) 1H, NH); ¹³C NMR (125 MHz, CDCl₃): δ =24.1 (t, CH₂), 24.9 (t, CH₂), 31.6 (t, CH₂), 32.9 (t, CH₂), 54.1 (d, CH), 59.6 (d, CH), 86.0 (ddd, J_{CF} =41.7, 24.9 Hz, C-3'/C-5'), 87.8 (m_c, C-3/C-5), 91.7 (ddd, J_{CF} =22.4, 5.6 Hz, C-3'/C-5'), 158.6 (ddd, J_{CF} =19.9, 14.3 Hz, C-2'), 159.7 (ddd, J_{CF} =11.9 Hz, C-4), 163.4 (ddd, J_{CF} =237, 20.3 Hz, C-2/C-6), 164.1 (ddd, J_{CF} =236, 17.1 Hz, C-6'), 172.1 (ddd, J_{CF} =257, 13.9 Hz, C-4'); ¹⁹F NMR (376 MHz, CDCl₃): δ =-98.2 (m_c, 1F, 4'-F), -71.2 (s, 2F, 2-F), -66.8 (m_c, 1F, 6'-F); HR-MS (ESI-TOF): m/z=341.1382, calcd. for C₁₆H₁₆F₄N₄: 341.1389 [M+H]⁺.

32: mp 259–261 °C [250–252 °C for *R*,*R*-isomer, $[\alpha]_D^{20}$: +89.2 (*c*=0.60, MeOH]; ¹H NMR (500 MHz, acetone-*d*₆): δ =1.36–1.55 (m, 4H, CH₂), 1.76 (m_c, 2H, CH₂), 2.06–2.12 (m, 2H, CH₂), 3.54 (m_c, 2H, CH), 6.04 (s, 4H, 3-H/5-H), 6.56 (br s, 2H, NH); ¹³C NMR (125 MHz, acetone-*d*₆): δ = 24.4 (t, CH₂), 32.1 (t, CH₂), 56.5 (d, CH), 87.4 (m_c, C-3/C-5), 160.9 (ddt, *J*_{C,F}=12.1 Hz, C-4), 163.3 (dd, *J*_{C,F}=233, 20.8 Hz, C-2); ¹⁹F NMR (376 MHz, acetone-*d*₆): δ =-73.8 (s, 4F, 2-F); HR-MS (ESI-TOF): *m*/*z*=341.1380, calcd. for C₁₆H₁₆F₄N₄: 341.1389 [M+H]⁺.

2,3,5-Trifluoro-4-morpholinylpyridine (34): According to GP2, 2,3,5,6-tetrafluoro-4-morpholinylpyridine (6) (0.470 g, 2.00 mmol) and hydrazine monohydrate (2.00 g, 40.0 mmol, 20 equiv.) were dissolved in ethanol (12 mL) and stirred for 3 h under reflux. The mixture was concentrated and the residue was dissolved in CH2Cl2 (75 mL) and washed with water (2×50 mL). The organic phase was dried and concentrated to give crude **33** as a yellow solid; yield: 0.469 g (94%). The crude product 33 (0.124 g, 0.50 mmol) was suspended in water (1 mL) and a solution of CuSO₄·5 H₂O (0.81 g, 3.25 mmol, 6.5 equiv.) in water (5 mL) was added drop-wise. The resulting mixture was heated to reflux for 1 h. Purification by FLC (hexanes/EtOAc 2:1) gave pyridine 34 as a colorless solid; yield: 90 mg (78% over 2 steps); mp 33-34°C. ¹H NMR (500 MHz, CDCl₃): $\delta = 3.43$ (m_c, 4H, CH₂N), 3.80 (m_c , 4H, CH₂O), 7.66 (m_c , 1H, 2-H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 50.5$ (t, CH₂N), 67.1 (t, CH₂O), 128.2 (d, C-6), 137.7 (s, C-4), 149.8, 150.0 (2 s, C-2, C-3), 150.6 (s, C-5); ¹⁹F NMR (471 MHz, CDCl₃): $\delta = -150.7$ (m_c, 1F, 3-F), -139.4 (m_c, 1F, 5-F), -89.9 (m_c, 1F, 2-F); IR (ATR): $\tilde{\nu} =$ 2965-2860 (C-H), 1615, 1565, 1510 (C=C, C=N), 1450, 1255, 1180, 1120, 1100 (C-F) cm⁻¹; HR-MS (ESI-TOF): m/z =219.0749, calcd. for C₉H₉F₃N₂O: 219.0749 [M+H]⁺, m/z =241.0575, calcd. for [M+Na]⁺: 241.0559; anal. calcd. (%) for C₉H₉F₃N₂O (218.2): C 49.55, H 4.16, N 12.84; found: C 49.44, H 4.22, N 12.95.

3,5-Difluoro-4-morpholinylpyridine (36): According to **GP2**, 2,3,5-trifluoro-4-morpholinylpyridine (**34**) (0.110 g, 0.50 mmol) and hydrazine monohydrate (1.00 g, 20.0 mmol, 40 equiv.) were dissolved in ethanol (7 mL) and stirred for 48 h under reflux. The mixture was concentrated and the residue was dissolved in CH2Cl2 (50 mL) and washed with water (2×50 mL). The organic phase was dried and concentrated to give 35 as a red solid (yield: 93 mg). The crude product was suspended in water (10 mL) and the solution of $CuSO_4 \cdot 5H_2O$ (0.66 g, 2.63 mmol, 6.5 equiv.) in water (10 mL) was added drop-wise. The resulting mixture was heated to reflux for 1 h. Purification by FLC (hexanes/ EtOAc 10:1) gave pyridine 36 as a colorless solid; yield: 35 mg (35% over 2 steps); mp 56–58 °C. ¹H NMR (500 MHz, $CDCl_3$): $\delta = 3.39 (m_c, 4H, CH_2N), 3.81 (m_c, 4H, CH_2O), 8.15$ (s, 2H, 2-H); ¹³C NMR (CDCl₃, 125 MHz): $\delta = 50.6$ (t, CH₂N), 67.2 (t, CH₂O), 134.4 (s, C-4), 135.1 (d, C-2), 136.2 (s, C-3); ¹⁹F NMR (CDCl₃, 376 MHz): $\delta = -137.8$ (s, 2F, 3-F); IR (ATR): $\tilde{\nu} = 3030$ (=C–H), 2955, 2920, 2855 (C–H), 1600, 1550, 1505 (C=C, C=N), 1450, 1250, 1150, 1115 (C–F) cm⁻¹; HR-MS (ESI-TOF): m/z = 201.0839, calcd. for C₉H₁₀F₂N₂O: 201.0834 [M+H]⁺.

Advanced >

Catalysis

Synthesis &

2-Fluoro-4-morpholinylpyridine (39): According to GP2, 2,6-difluoro-4-morpholinylpyridine (9) (0.100 g, 0.50 mmol) and hydrazine monohydrate (0.500 g, 10.0 mmol, 20 equiv.) were dissolved in ethanol (7 mL) and stirred for 4 h under reflux. The mixture was concentrated and the residue was dissolved in CH_2Cl_2 (50 mL) and washed with water (2× 50 mL). The organic phase was dried and concentrated to give 38 as a yellow solid; yield: 84 mg (79%). The crude product 38 (53 mg, 0.25 mmol) was suspended in water (1 mL) and the solution of $CuSO_4 \cdot 5H_2O$ (0.41 g, 1.62 mmol, 6.5 equiv.) in water (10 mL) was added drop-wise. The resulting mixture was heated to reflux for 1 h. Purification by FLC (hexanes/EtOAc 2:1, 1:1) furnished pyridine 39 as a colorless solid; yield: 15 mg (33%, 26% over 2 steps); mp 153-154 °C. ¹H NMR (500 MHz, CDCl₃): $\delta = 3.29$ (m_c, 4H, CH₂N), 3.82 (m_c, 4H, CH₂O), 6.18 (d, J=1.4 Hz, 1H, 3-H), 6.54 (m_c, 1H, 5-H), 7.90 (d, J = 6.1 Hz, 1H, 6-H); ¹³C NMR $(125 \text{ MHz}, \text{CDCl}_3): \delta = 46.4 \text{ (t, CH}_2\text{N}), 66.3 \text{ (t, CH}_2\text{O}), 92.1$ (d, C-3), 106.5 (d, C-5), 147.8 (d, C-6), 159.4 (s, C-4), 165.9 (s, C-2); ¹⁹F NMR (376 MHz, CDCl₃): $\delta = -68.9$ (s, 1F, 2-F); IR (ATR): \tilde{v} =3110, 3020 (=C-H), 2975, 2960, 2925, 2860 (C-H), 1610, 1550, 1505 (C=C, C=N), 1450, 1195, 1120 (C-F) cm⁻¹; HR-MS (ESI-TOF): m/z = 183.0924, calcd. for $C_9H_{11}FN_2O$: 183.0928 [M+H]⁺, m/z = 205.0741, calcd. for $[M+Na]^+$: 205.0748, m/z = 221.0491, calcd. for $[M+K]^+$: 221.0487, m/z = 387.1590, calcd. for $[2M + Na]^+$: 387.1603; anal. calcd. (%) for C₉H₁₁FN₂O (182.2): C 59.33, H 6.09, N 15.38; found: C 59.34, H 5.92, N 15.22.

N,*N*'-Dimethyl-*N*,*N*'-bis(2,3,5-trifluoropyridine-4-yl)-

ethane-1,2-diamine (41): According to GP2, pyridine derivative 23 (0.193 g, 0.50 mmol) and hydrazine monohydrate (1.00 g, 20.0 mmol, 40 equiv.) were dissolved in ethanol (10 mL) and stirred for 3 h under reflux. The mixture was concentrated and the residue was dissolved in CH₂Cl₂ (50 mL) and washed with water (2×50 mL). The organic phase was dried and concentrated to give 40 as a yellow solid; yield: 203 mg. The crude product 40 (0.183 g, 0.45 mmol) was suspended in water (1 mL) and a solution of $CuSO_4 \cdot 5 H_2O$ (1.45 g, 5.80 mmol, 13 equiv.) in water (16 mL) was added drop-wise. The resulting mixture was refluxed for 1 h. Purification by FLC (hexanes/EtOAc 10:1) provided pyridine 41 as a yellow solid; yield: 68 mg (44% over 2 steps); mp 113–114 °C. ¹H NMR (500 MHz, CDCl₃): $\delta = 3.15$ $(t, J = 3.3 \text{ Hz}, 6 \text{ H}, \text{ CH}_3), 3.64 (s, 4 \text{ H}, \text{ CH}_2), 7.61 (m_c, 2 \text{ H}, 2 \text{ H})$ H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 40.8$ (q, CH₃), 52.5 (t, CH₂), 128.1 (d, C-6), 137.1 (s, C-2), 137.3 (s, C-4), 150.0 (s, C-5), 169.4 (s, C-3); $^{19}{\rm F}$ NMR (376 MHz, CDCl₃): δ = –153.5 $(m_c, 2F, 3-F), -142.0 (m_c, 2F, 5-F), -92.3 (m_c, 2F, 2-F); IR$ (ATR): \tilde{v} = 3015–2835 (C–H), 1610, 1560, 1525 (C=C, C=N), 1455, 1240, 1215, 1110 (C-F) cm⁻¹; HR-MS (ESI-TOF): m/z = 351.1046, calcd. for $C_{14}H_{12}F_6N_4$: 351.1039 [M+H]⁺, m/z = 373.0866, calcd. for $[M + Na]^+$: 373.0858; anal. calcd. (%) for C₁₄H₁₂F₆N₄ (350.3): C 48.01, H 3.45, N 16.00; found: C 40.08, H 3.44, N 16.11.

rac-trans-N,N'-Dimethyl-*N,N'*-bis(2,3,5-trifluoropyridine-4-yl)cyclohexane-1,2-diamine (43): According to GP2, pyri-

dine derivative rac-19 (0.220 g, 0.50 mmol) and hydrazine monohydrate (1.00 g, 20.0 mmol, 40 equiv.) were dissolved in ethanol (10 mL) and stirred for 3 h under reflux. The mixture was concentrated and the residue was dissolved in CH_2Cl_2 (50 mL) and washed with water (2×75 mL). The organic phase was dried and concentrated to give 42 as a yellow solid; yield: 230 mg. The crude product 42 (0.205 g, 0.44 mmol) was suspended in water (1 mL) and a solution of $CuSO_4 \cdot 5H_2O$ (1.43 g, 5.74 mmol, 13 equiv.) in water (20 mL) was added drop-wise. The resulting mixture was heated to reflux for 1 h. Purification by FLC (hexanes/EtOAc 15:1) provided pyridine 43 as a colorless solid; yield: 100 mg (50% over two steps); mp 118-119°C. ¹H NMR (500 MHz, CDCl₃): $\delta = 1.35$ (m_c, 2H, CH₂), 1.65–1.74 (m, 2H, CH₂), 1.83–1.89 (m, 2 H, CH₂), 2.08–2.11 (m, 2 H, CH₂), 2.70 (t, J =3.1 Hz, 6H, CH₃), 3.58–3.60 (m, 2H, CH), 7.64 (m_c, 2H, 6-H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 25.3$ (t, CH₂), 30.2 (t, CH₂), 33.3 (q, CH₃), 61.7 (d, CH), 128.3 (d, C-6), 136.9 (s, C-2), 138.5 (s, C-4), 150.1 (s, C-3), 151.1 (s, C-5); ¹⁹F NMR $(376 \text{ MHz}, \text{CDCl}_3): \delta = -150.6 \text{ (m}_c, 2\text{ F}, 3\text{-F}), -139.1 \text{ (m}_c, 2\text{ F},$ 5-F), -90.5 (m_c, 2F, 2-F); IR (ATR): $\tilde{v} = 2940-2830$ (C-H), 1610, 1515 (C=C, C=N), 1455, 1250, 1210, 1140 (C-F) cm⁻¹; HR-MS (ESI-TOF): m/z = 405.1523, calcd. for $C_{18}H_{18}F_6N_4$: 405.1508 $[M+H]^+$, m/z = 427.1347, calcd. for $[M+Na]^+$: 427.1328; anal. calcd. (%) for $C_{18}H_{18}F_6N_4$ (404.4): C 53.47, H 4.49, N 13.86; found: C 53.33, H 4.40, N 13.72.

3,5-Difluoro-4-morpholinopyridine (**36**): According to **GP3**, 2,3,5,6-tetrafluoro-4-morpholinopyridine (**6**) (50 mg, 0.21 mmol), titanocene difluoride (7 mg, 0.032 mmol, 15 mol%), diphenylsilane (0.235 mL, 1.27 mmol, 6 equiv.) and dry 1,4-dioxane (2 mL) were stirred for 18 h at 110 °C. The product was isolated after FLC (hexanes/ethyl acetate 4:1, 1:1) as a colorless solid; yield: 40 mg (95%); mp 56–58 °C. ¹H NMR (500 MHz, CDCl₃): δ =3.39 (m_c, 4H, CH₂N), 3.81 (m_c, 4H, CH₂O), 8.15 (s, 2H, 2-H); ¹³C NMR (125 MHz, CDCl₃): δ =50.6 (t, CH₂N), 67.2 (t, CH₂O), 134.4 (s, C-4), 135.1 (d, C-2), 136.2 (s, C-3); ¹⁹F NMR (376 MHz, CDCl₃): δ =-137.8 (s, 2F, 3-F); IR (ATR): $\tilde{\nu}$ =3030 (=C-H), 2955, 2920, 2855 (C-H), 1600, 1550, 1505 (C=C, C=N), 1450, 1250, 1150, 1115 (C-F) cm⁻¹; MS (ESI-TOF): m/z = 201.0839, calcd. for C₉H₁₀F₂N₂O: 201.0834 [M+H]⁺.

4-Morpholinopyridine (44): According to **GP3**, 2,6-difluoro-4-morpholinopyridine (9) (100 mg, 0.50 mmol), titanocene difluoride (16 mg, 0.08 mmol, 15 mol%), diphenylsilane (0.28 mL, 1.50 mmol, 3 equiv.) and dry 1,4-dioxane (2 mL) were stirred for 18 h at 110 °C. Product **44** was isolated after FLC (CH₂Cl₂/MeOH 95:5) as a colorless solid; yield: 80 mg (98%); mp 105–107 °C (lit.^[18] 112–115 °C). ¹H NMR (500 MHz, CD₃OD): δ =3.30 (t, *J*=8.1 Hz, 4H, CH₂N), 3.77 (t, *J*=8.1 Hz, 4H, CH₂O), 6.81 (d, *J*≈6 Hz, 2H, 3-H), 8.13 (d, *J*≈6 Hz, 2H, 2-H); ¹³C NMR (125 MHz, CD₃OD): δ =45.7 (t, CH₂N), 66.1 (t, CH₂O), 108.1 (d, C-3), 148.8 (d, C-2), 155.9 (s, C-4); IR (ATR): \tilde{v} =3025 (=C−H), 2965–2880 (C−H), 1600–1535 (C=C, C=N), 1450, 1365, 1235, cm⁻¹; HR-MS (ESI-TOF): *m/z*=165.1034, calcd. for C₉H₁₃N₂O: 165.1028 [M+H]⁺.

N,N'-Dimethyl-*N,N'*-bis(3,5-difluoropyridin-4-yl)ethane-1,2-diamine (45): According to GP3, *N,N'*-dimethyl-*N,N'*bis(2,3,5,6-tetrafluoropyridin-4-yl)ethane-1,2-diamine (23) (250 mg, 0.65 mmol), titanocene difluoride (43 mg, 0.20 mmol, 30 mol%), diphenylsilane (0.73 mL, 3.90 mmol, 6 equiv.) and dry 1,4-dioxane (4 mL) were stirred for 18 h at 110 °C. Product **45** was isolated after FLC (hexanes/EtOAc 1:1) as a colorless solid; yield: 112 mg (55%); mp 146– 148 °C. ¹H NMR (500 MHz, CDCl₃): δ =3.04 (t, *J*=2.9 Hz, 6H, CH₃), 3.53 (s, 4H, CH₂), 8.04 (s, 4H, 2-H, 6-H); ¹³C NMR (CDCl₃, 125 MHz): δ =40.8 (q, CH₃), 52.5 (t, CH₂), 134.3 (s, C-4), 134.9 (d, C-2), 152.1 (s, C-3); ¹⁹F NMR (CDCl₃, 376 MHz): δ =-138.3 (s, 4F, 3-F); IR (ATR): \tilde{v} = 3010 (=C-H), 2920, 2850 (C-H), 1600, 1525 (C=C, C=N), 1460, 1225, 1190, 1150 (C-F) cm⁻¹; HR-MS (ESI-TOF): *m*/*z*=315.1226, calcd. for C₁₄H₁₄F₄N₄: 315.1227 [M+H]⁺.

rac-trans-N,N'-Dimethyl-N,N'-bis(3,5-difluoropyridin-4yl)cyclohexane-1,2-diamine (46): According to GP3, rac-19 1.36 mmol), titanocene difluoride (600 mg, (88 mg, 0.41 mmol, 30 mol%), diphenylsilane (1.51 mL, 8.16 mmol, 6 equiv.) and dry 1,4-dioxane (6 mL) were stirred for 18 h at 110°C. Product 46 was isolated after FLC (hexanes/EtOAc 4:1) as a colorless solid; yield: 345 mg (69%); mp 134-135 °C. ¹H NMR (500 MHz, CDCl₃): $\delta = 1.33$ (m_c, 2H, CH₂), 1.62-1.71 (m, 2H, CH₂), 1.83-1.86 (m, 2H, CH₂), 2.08-2.11 (m, 2H, CH₂), 2.66 (t, J=2.7 Hz, 6H, CH₃), 3.55 (m_c, 2H, CH), 8.08 (br s, 4H, 2-H, 6-H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 25.4$ (t, CH₂), 30.2 (t, CH₂), 33.4 (q, CH₃), 61.5 (d, CH), 134.8 (d, C-2), 135.4 (s, C-4), 152.0 (s, C-3); ¹⁹F NMR (376 MHz, CDCl₃): $\delta = -137.5$ (s, 4 F, 3-F); IR (ATR): $\tilde{v} = 3055$ (=C-H), 2925–2855 (C-H), 1600, 1515 (C=C, C=N), 1425, 1200, 1145, 1150 (C-F) cm⁻¹; HR-MS (ESI-TOF): m/z = 369.1693, calcd. for C₁₈H₂₁F₄N₄: 369.1697 $[M + H]^+$.

N,N'-Dimethyl-N,N'-bis(pyridin-4-yl)ethane-1,2-diamine (48): According to GP3, N,N'-dimethyl-N,N'-bis(2,6difluoropyridine-4-yl)ethane-1,2-diamine (26) (145 mg, 0.46 mmol), titanocene difluoride (30 mg, 0.14 mmol, 30 mol%), diphenylsilane (0.51 mL, 2.76 mmol, 6 equiv.) and dry 1,4-dioxane (3 mL) were stirred for 24 h at 110 °C. Product 48 was isolated after FLC [CH₂Cl₂/MeOH/NH₃ in MeOH (7N), 95:5:2] as a colorless solid; yield: 99 mg (89%); mp 114–115°C. ¹H NMR (400 MHz, CDCl₃): $\delta =$ 2.92 (s, 6H, CH₃), 3.53 (s, 4H, CH₂), 6.43 (dd, J=4.9, 1.6 Hz, 4H, 3-H), 8.21 (dd, J=4.9, 1.6 Hz, 4H, 2-H); ¹³C NMR (125 MHz, CDCl₃): $\delta = 38.2$ (q, CH₃), 48.6 (t, CH₂), 106.5 (d, C-3), 150.3 (d, C-2), 153.1 (s, C-4); IR (ATR): v=3090-3030 (=C-H), 2990, 2805 (C-H), 1605, 1520 (C=C, C=N) cm⁻¹; HR-MS (ESI-TOF): m/z = 243.1604, calcd. for $C_{14}H_{18}N_4$: 243.1610 $[M+H]^+$; anal. calcd. (%) for C₁₄H₁₈N₄ (242.2): C 65.73, H 7.68, N 21.90; found: C 65.72, H 7.72, N 22.08.

rac-trans-N,N'-Bis(pyridin-4-yl)cyclohexane-1,2-diamine (49): According to GP3, rac-trans-N,N'-bis(2,6-difluoropyridin-4-yl)cyclohexane-1,2-diamine (32) (50 mg, 0.15 mmol), titanocene difluoride (10 mg, 0.04 mmol, 30 mol%), diphenylsilane (0.163 mL, 0.88 mmol, 6 equiv.) and dry 1,4-dioxane (2 mL) were stirred for 20 h at 110 °C. Product 49 was isolated after FLC [EtOAc/MeOH/NH₃ in MeOH (7N), 95:5:2] and HPLC (RP, MeOH/H₂O, 70:30) as a colorless solid; yield: 33 mg (83%); mp 293-295 °C. ¹H NMR (400 MHz, CD₃OD): $\delta = 1.30-1.45$ (m, 4H, CH₂), 1.79 (m_c, 2H, CH₂), 2.05 (m_c, 2H, CH₂), 3.34–3.41 (m, 2H, CH), 6.44 (d, J=5.8 Hz, 4H, 3-H), 7.82 (d, J=4.7 Hz, 4H, 2-H); ¹³C NMR (101 MHz, CD₃OD): $\delta = 25.9$ (t, CH₂), 33.3 (t, CH₂), 57.1 (d, CH), 108.5 (d, C-3), 149.2 (d, C-2), 155.8 (s, C-4); HR-MS (ESI-TOF): m/z = 269.1770, calcd. for $C_{17}H_{21}N_4$: 269.1761 [M+H]⁺.

3a,7a-rac-trans-1,3-Bis(2,6-difluoropyridin-4-yl)octahydro-1H-benzo[d]imidazole (rac-50): To a stirred solution of compound rac-32 (70 mg, 0.206 mmol) in formaldehyde (1.8 mL of a 37% w/v solution in water, 20.6 mmol, 100 equiv.), formic acid (63 mg, 1.36 mmol, 6.7 equiv.) was added and the resulting mixture was heated to reflux for 24 h. The reaction was quenched by water (30 mL) and extracted with CH_2Cl_2 (3×50 mL). The product *rac*-50 was obtained after FLC (hexanes/EtOAc 3:1) as a colorless solid; yield: 51 mg (70%); mp 192–194 °C. ¹H NMR (400 MHz, CDCl₃): $\delta =$ 1.50-1.67 (m, 4H, CH₂), 2.02 (m_c, 2H, CH₂), 2.64 (m_c, 2H, CH₂), 3.34 (m_c, 2H, CH), 4.75 (s, 2H, N-CH₂-N), 6.15 (s, 4H, 3-H); ¹³C NMR (101 MHz, CDCl₃): $\delta = 24.0$ (t, CH₂), 30.0 (t, CH₂), 65.9 (d, CH), 70.7 (t, CH₂), 91.6 (m_c, C-3), 159.2 (dd, J=11.1 Hz, C-4), 162.9 (dd, J=240, 20.0 Hz, C-2); ¹⁹F NMR (376 MHz, CDCl₃): $\delta = -68.9$ (s, 4F, 2-F); MS (ESI-TOF): m/z = 375.1208, calcd. for $C_{17}H_{16}F_4N_4Na$: 375.1209 [M+Na]⁺.

(*R*,*R*)-*trans-N*,*N*'-Dimethyl-*N*,*N*'-bis(2,6-difluoropyridin-4-yl)cyclohexane-1,2-diamine (31): Enantiopure (*R*,*R*)-*trans-N*,*N*'-bis(2,6-difluoropyridin-4-yl)cyclohexane-1,2-diamine (32) (320 mg, 0.94 mmol) was dissolved in THF (10 mL) and NaH (228 mg, 6.65 mmol, 70% in mineral oil, 7 equiv.) was added at room temperature and the resulting mixture was stirred for 30 min. Then, methyl iodide (820 mg, 5.78 mmol, 6 equiv.) was added drop-wise and the resulting mixture was stirred for 48 h. The reaction was quenched by careful water addition and extraction (3×50 mL, CH₂Cl₂) and chromatographic purification (hexanes/EtOAc, 6:1) gave the product (*R*,*R*)-**31**; yield: 295 mg (85%); mp 201–203°C; $[\alpha]_D^{20}$: +105.7 (*c*=1.4, CHCl₃).

3a,7a-rac-trans-1,3-Bis(pyridin-4-yl)octahydro-1H-benzo-[d]imidazole (51): According to GP3, compound rac-50 0.085 mmol), titanocene difluoride (30 mg, (4 mg. 0.02 mmol, 20 mol%), diphenylsilane (0.094 mL, 0.51 mmol, 6 equiv.) and dry 1,4-dioxane (2 mL) were stirred for 48 h at 110°C. Product 51 was isolated after FLC [EtOAc/NH₃ in MeOH (7N), 95:5] as a slightly yellow solid; yield: 22 mg (92%); mp 216–218 °C. ¹H NMR (400 MHz, CD₃OD): $\delta =$ 1.52 (m_c, 4H, CH₂), 1.97 (m_c, 2H, CH₂), 2.64 (m_c, 2H, CH₂), 3.25 (m_c, 2H, CH), 4.73 (s, 2H, N-CH₂-N), 6.66 (d, J =4.6 Hz, 4H, 3-H), 8.33 (d, J = 4.4 Hz, 4H, 2-H); ¹³C NMR (101 MHz, CD₃OD): $\delta = 24.3$ (t, CH₂), 30.3 (t, CH₂), 65.6 (d, CH), 71.6 (t, CH₂), 101.8 (d, C-3), 150.2 (d, C-2), 153.2 (s, C-4); HR-MS (ESI-TOF): m/z = 281.1766, calcd. for $C_{17}H_{21}N_4$: 281.1761 [M+H]+.

(*R*,*R*)-*trans-N*,*N*'-Dimethyl-*N*,*N*'-bis(pyridin-4-yl)cyclohexane-1,2-diamine (52): According to GP3, (*R*,*R*)-*N*,*N*'-dimethyl-*N*,*N*'-bis(2,6-difluoropyridin-4-yl)cyclohexane-1,2-diamine (31) (24 mg, 0.065 mmol), titanocene difluoride (5 mg, 0.02 mmol, 30 mol%), diphenylsilane (0.073 mL, 0.39 mmol, 6 equiv.) and dry 1,4-dioxane (2 mL) were stirred for 24 h at 110 °C. Product 52 was isolated after FLC [CH₂Cl₂/MeOH/NH₃ in MeOH (7N), 95:5:2] as a slightly yellow solid; yield: 18 mg (95%); mp 269–271 °C; [α]_D²⁰. +157.3 (*c*=0.50, MeOH). ¹H NMR (500 MHz, CDCl₃): *δ*= 1.42–1.48 (m, 2H, CH₂), 1.56–1.62 (m, 2H, CH₂), 1.89–1.94 (m, 4H, CH₂), 2.59 (s, 6H, CH₃), 3.83 (dd, *J*=5.8, 3.1 Hz, 2H, CH), 6.49 (d, *J*≈6 Hz 4H, 3-H), 8.20 (d, *J*≈6 Hz, 4H, 2-H); ¹³C NMR (126 MHz, CDCl₃): *δ*=25.2 (t, CH₂), 29.2 (t, CH₂), 30.5 (q, CH₃), 58.0 (d, CH), 106.7 (d, C-3), 150.1 (d, C-2), 153.7 (s, C-4); HR-MS (ESI-TOF): m/z = 297.2082, calcd. for C₁₈H₂₄N₄: 297.2079 [M+H]⁺.

Advanced >

Copies of NMR spectra of all compounds can be found in the Supporting Information.

Acknowledgements

Generous support of this work by the Deutsche Forschungsgemeinschaft (SFB 765 "Multivalency" and GRK 1582 "Fluorine as Key Element") and Bayer HealthCare is most gratefully acknowledged. We also thank Dr. Moritz F. Kühnel for experimental advice and helpful discussions and Mrs. V. Rojek for preliminary experiments.

References

- Review on the amination of nitrogen heterocycles: H. Vorbrüggen, in: *Advances in Heterocyclic Chemistry*, (Ed.: A. R. Katritzky), Elsevier, Vol. 49, **1990**, pp 117– 192.
- [2] Reviews: a) G. Höfle, W. Steglich, H. Vorbrüggen, Angew. Chem. 1978, 90, 602–615; Angew. Chem. Int. Ed. Engl. 1978, 17, 569–583; b) A. C. Spivey, S. Arseniyadis, Angew. Chem. 2004, 116, 5552–5557; Angew. Chem. Int. Ed. 2004, 43, 5436–5441; c) N. De Rycke, F. Couty, O. R. P. David, Chem. Eur. J. 2011, 17, 12852– 12871.
- [3] Selected studies on new DMAP analogues: a) S. Xu, I. Held, B. Kempf, H. Mayr, W. Steglich, H. Zipse, *Chem. Eur. J.* 2005, *11*, 4751–4757; b) I. Held, E. Larionov, C. Bozler, F. Wagner, H. Zipse, *Synthesis* 2009, 2267–2277; c) V. D'Elia, Y. Liu, H. Zipse, *Eur. J. Org. Chem.* 2011, 1527–1533; d) R. Tandon, T. A. Nigst, H. Zipse, *Eur. J. Org. Chem.* 2013, 5423–5430; e) R. Tandon, T. Unzner, T. A. Nigst, N. De Rycke, P. Mayer, B. Wendt, O. R. P. David, H. Zipse, *Chem. Eur. J.* 2013, *19*, 6435–6442; f) P. Hommes, C. Fischer, C. Lindner, H. Zipse, H.-U. Reissig, *Angew. Chem.* 2014, *126*, 7778–7782; *Angew. Chem. Int. Ed.* 2014, *53*, 7647–7651.
- [4] Review on the synthesis and use of enantiopure DMAP analogues: T. Furuta, T. Kawabata, in: Science of Synthesis: Asymmetric Organocatalysis, (Ed.: B. List), Thieme, Stuttgart, 2012, vol. 1, pp 497–546.
- [5] Selected reports on the stabilization of nanoparticles and nanotubes: a) D. Gittins, F. Caruso, Angew. Chem. 2001, 113, 3089–3092; Angew. Chem. Int. Ed. 2001, 40, 3001–3004; b) V. Gandubert, R. Lennox, Langmuir 2005, 21, 6532–6539; c) S. Rucareanu, V. J. Gandubert, R. B. Lennox, Chem. Mater. 2006, 18, 4674–4680; d) K. A. Flanagan, J. A. Sullivan, H. Müller-Bunz, Langmuir 2007, 23, 12508–12520; e) F. Muench, U. Kunz, C. Neetzel, S. Lauterbach, H.-J. Kleebe, W. Ensinger, Langmuir 2011, 27, 430–435; f) J. Milette, V. Toader, L. Reven, R. B. Lennox, J. Mater. Chem. 2011, 21, 9043–9050.
- [6] Nucleophilic substitutions on 4-halopyridine derivatives failed even in the presence of palladium catalysts:
 a) M. Taszarek, *Dissertation*, Freie Universität Berlin, 2011;
 b) G. Podolan, unpublished results. For examples

of palladium-catalyzed aminations of halopyridine derivatives, see: c) J. P. Wolfe, S. Wagaw, J. F. Marcoux, S. L. Buchwald, *Acc. Chem. Res.* **1998**, *31*, 805–818; d) J. F. Hartwig, M. Koley, *Acc. Chem. Res.* **1998**, *31*, 851–860; e) K. W. Anderson, M. Mendez-Perez, J. Priego, S. L. Buchwald, *J. Org. Chem.* **2003**, *68*, 9563– 9573. For an example of a successful palladium-catalyzed nucleophilic substitution of *trans*-1,2-diaminocyclohexane with 2,4-dichloroquinoline, see: f) T. A. Davis, M. C. Dobish, K. E. Schwieter, A. C. Chun, J. N. Johnston, *Org. Synth.* **2012**, *89*, 380–393.

- [7] For a preliminary report on our results, see: G. Podolan, D. Lentz, H.-U. Reissig, Angew. Chem. 2013, 125, 9669–9672; Angew. Chem. Int. Ed. 2013, 52, 9491–9494.
- [8] Reviews: a) R. D. Chambers, C. R. Sargent, Adv. Heterocycl. Chem. 1981, 28, 1–71; b) G. M. Brooke, J. Fluorine Chem. 1997, 86, 1–76; c) R. D. Chambers, Fluorine in Organic Chemistry; Blackwell: Oxford, 2004. Selected original reports: d) R. E. Banks, J. E. Burgess, W. M. Cheng, R. N. Haszeldine, J. Chem. Soc. 1965, 575–581; e) M. Schlosser, C. Bobbio, T. Rausis, J. Org. Chem. 2005, 70, 2494–2502; f) G. Sandford, R. Slater, D. S. Yufit, J. A. K. Howard, A. Vong, J. Org. Chem. 2005, 70, 7208–7216; g) C. A. Hargreaves, G. Sandford, R. Slater, D. S. Yufit, J. A. K. Howard, A. Vong, Tetrahedron 2007, 63, 5204–5211; h) R. R. Karimi, M. M. Shoshtari, S. H. Uderji, R. Kia, J. Fluorine Chem. 2011, 132, 285–290; i) R. R. Karimi, M. M. Shoshtari, A. Darehkordi, Ultrason. Sonochem. 2011, 18, 258–263.
- [9] Selected recent reviews: a) T. Braun, F. Wehmeier, Eur. J. Inorg. Chem. 2011, 613-625; b) J.-F. Paquin, Synlett 2011, 289–293; c) E. Clot, O. Eisenstein, N. Jasim, S. A. Macgregor, J. E. McGrady, R. N. Perutz, Acc. Chem. Res. 2011, 44, 333-348; d) A. Nova, R. Mas-Ballesté, A. Lledós, Organometallics 2012, 31, 1245-1256; e) M. Klahn, U. Rosenthal, Organometallics 2012, 31, 1235-1244; f) M. F. Kühnel, D. Lentz, T. Braun, Angew. Chem. 2013, 125, 3412-3433; Angew. Chem. Int. Ed. 2013, 52, 3328–3348; g) M. K. Whittlesey, E. Peris, ACS Catal. 2014, 4, 3152-3159. Selected recent original reports: h) J. A. Panetier, S. A. Macgregor, M. K. Whittlesey, Angew. Chem. 2011, 123, 2835-2838; Angew. Chem. Int. Ed. 2011, 50, 2783-2786; i) C. B. Caputo, D. W. Stephan, Organometallics 2012, 31, 27-30; j) P. Fischer, K. Götz, A. Eichhorn, U. Radius, Organometallics 2012, 31, 1374-1383; k) S. Yow, S. J. Gates, A. J. P. White, M. R. Crimmin, Angew. Chem. 2012, 124, 12727-12731; Angew. Chem. Int. Ed. 2012, 51, 12559–12563; l) Z. Chen, C.-Y. He, Z. Yin, L. Chen, Y. He, X. Zhang, Angew. Chem. 2013, 125, 5925-5929; Angew. Chem. Int. Ed. 2013, 52, 5813-5817; m) S. M.

Senaweera, A. Singh, J. D. Weaver, J. Am. Chem. Soc.
2014, 136, 3002–3005; n) A. Arévalo, A. Tlahuext-Aca,
M. Flores-Alamo, J. J. Garcia, J. Am. Chem. Soc. 2014, 136, 4634–4639.

- [10] Selected reviews: a) M. Schlosser, Angew. Chem. 1998, 110, 1538-1556; Angew. Chem. Int. Ed. 1998, 37, 1496-1513; b) P. Kirsch, Modern Fluoroorganic Chemistry, Wiley-VCH, Weinheim, 2005; c) W. R. Dolbier Jr, J. Fluorine Chem. 2005, 126, 157-163; d) J.-P. Bégué, D. Bonnet-Delpon, J. Fluorine Chem. 2006, 127, 992-1012; e) S. Purser, P. R. Moore, S. Swallow, V. Gouverneur, Chem. Soc. Rev. 2008, 37, 320-330; f) A. Tressaud, G. Haufe, Fluorine and Health; Molecular Imaging, Biomedical Materials and Pharmaceuticals, Elsevier, Amsterdam, 2008; g) T. Yamazaki, T. Taguchi, I. Ojima, (Eds.), Unique Properties of Fluorine and Their Relevance to Medicinal Chemistry and Chemical Biology, John Wiley & Sons: Chichester, UK, 2009; h) D. O'Hagan, J. Fluorine Chem. 2010, 131, 1071-1081; i) J. Wang, M. Sánchez-Roselló, J. L. Aceña, C. del Pozo, A.E. Sorochinsky, S. Fustero, V.A. Soloshonok, H. Liu, Chem. Rev. 2014, 114, 2432-2506.
- [11] C. Bobbio, T. Rausis, M. Schlosser, Chem. Eur. J. 2005, 11, 1903–1910.
- [12] For a recent review on the chemoselective reductions of functional groups by SmI₂, see: M. Szostak, M. Spain, D. J. Procter, *Chem. Soc. Rev.* 2013, 42, 9155– 9183.
- [13] a) M. F. Kühnel, D. Lentz, Angew. Chem. 2010, 122, 2995–2998; Angew. Chem. Int. Ed. 2010, 49, 2933–2936;
 b) M. F. Kühnel, Dissertation, Freie Universität Berlin, 2011; c) M. F. Kühnel, P. Holstein, M. Kliche, J. Krüger, S. Matthies, D. Nitsch, J. Schutt, M. Sparenberg, D. Lentz, Chem. Eur. J. 2012, 18, 10701–10714.
- [14] For the reduction of lactones with this reagent combination, see: X. Verdaguer, M. C. Hansen, S. C. Berk, S. L. Buchwald, J. Org. Chem. 1997, 62, 8522–8528.
- [15] For a brief mechanistic discussion of the HDF process, see ref.^[7]
- [16] The compound was already tested as chiral base in the enantioselective kinetic resolution of α -methylbenzylamine, however, no selectivity was found. We thank Dr. Stellios Arseniyadis (ESPCI) for these experiments. For a seminal publication, see: A. Kolleth, S. Christoph, S. Arseniyadis, J. Cossy, *Chem. Commun.* **2012**, *48*, 10511–10513.
- [17] W. J. Guilford, J. Dallas, D. Arnaiz, J. Labelled Cpd. Radiopharm. 2001, 44, 247–256.
- [18] S. Wagaw, S. L. Buchwald, J. Org. Chem. **1996**, 61, 7240–7241.